drugset / Trial / NCT00380718

Chemotherapy for Patients With Non-Small Cell Lung Cancer

NCT00380718

Phase 4 Completed 33 enrolled Eli Lilly and Company
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the efficacy and toxicity of pemetrexed dosing that is tailored to individual patient tolerance in patients with advanced non-small cell lung cancer (NSCLC).

Timeline

Start
2006-11
Primary completion
2008-09
Completion
2009-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Pemetrexed Small molecule 375 mg/m2 Intravenous
Subject Pemetrexed Small molecule 500 mg/m2 Intravenous
Subject Pemetrexed Small molecule 1000 mg/m2 Intravenous